WellDoc

The company develops mobile solutions to drive behavioral and clinical change in chronic disease. WellDoc’s goal is to improve patient self-management and help physicians overcome gaps in the delivery system to improve clinical outcomes and decrease cost. WellDoc is best known for its flagship product BlueStar, which is a digital therapeutic for adults with type 2 diabetes.

Welldoc home

Welldoc, Redox team-up to optimize provider interaction with chronic disease management platform

By ensuring bidirectional integration with EHRs and insights available at the point of care, the partnership will help optimize clinical decision support.
BlueStar

WellDoc validates potential of BlueStar to reduce healthcare costs

The company worked with Truven Health Analytics to show that BlueStar can save on average a range of $254 to $271 per user per month.
BlueStar C app

WellDoc’s diabetes management app BlueStar C coming to Samsung Health

BlueStar C is a diabetes health tool designed to aid individuals living with diabetes in managing their chronic condition.
Bluestar diabetes coaching app

WellDoc, HTAA team-up to address diabetes in trucking industry

WellDoc has also unveiled its consumer diabetes health app, BlueStar C, to aid individuals living with diabetes manage their chronic condition.

Non-prescription version of WellDoc’s BlueStar Digital Therapeutic gets FDA 510(k) clearance

The non-prescription version will have all the first-in-class features of BlueStar® Rx apart from an insulin calculator.
BlueStar app

WellDoc, AADE team-up to enhance the BlueStar Digital Therapeutic Platform

This is the first time AADE has partnered with an organization to provide its curriculum in a consumer-friendly digital format.
Verio Flex

LifeScan, WellDoc team-up to advance mobile care for Type 2 diabetes patients

The two companies will integrate LifeScan's OneTouch Verio Flex blood glucose monitoring system with WellDoc's BlueStar diabetes management platform.
BlueStar app

WellDoc gets $22M Series B for its diabetes management solution

The company will use the funds to accelerate adoption of BlueStar mobile prescription therapy for adults living with type 2 diabetes.
WellDoc BlueStar S

WellDoc, Samsung and OTN launch a pilot for patients with type 2 diabetes

The program will include a minimum of 300 people living with type 2 diabetes who will receive a prescription of BlueStar-S from their healthcare provider.